HIV, pneu­mo­coc­cal — and what? Mer­ck­'s un­ex­pect­ed pipeline high­light ex­cites a lit­tle biotech

In an R&D up­date dom­i­nat­ed by on­col­o­gy — most­ly Keytru­da, fol­lowed by Lyn­parza and Lenvi­ma — Mer­ck chose to high­light a pro­gram in sen­so­ry pathol­o­gy, an HIV drug, and a group of pneu­mo­coc­cal vac­cines. And that has made at least one biotech very hap­py.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN